Ollin Biosciences
- Health & Biotech
- Austin, Texas, US
- Founded 2023
- Private
- ollin.bio
Biotech developing OLN324, a biologic entering Phase 3 trials for diabetic macular edema and wet age-related macular degeneration.
$430MEquity raised in 2025–20262025 $100M · 2026 $330M · 2 equity rounds
$430MEquity raised, all time2 equity rounds sourced so far
—Latest valuationnot disclosed
Rounds over time log-scaled amounts
Funding history 2 rounds · 3 sources · newest first
Earlier rounds not yet sourced. Ollin Biosciences was founded in 2023 and raised before 17 Sep 2025; only the rounds below are sourced so far, so its all-time equity total understates its history.
- Series BAmount$330MPost-money—✓ Confirmed
- Launch financingAmount$100MPost-money—✓ Confirmed
- Earlier rounds not yet sourced
Investors 10
- ARCH Venture Partners2
- Monograph Capital2
- Mubadala2
- TCGX1
- Andreessen Horowitz
- Blackstone
- Commodore Capital
- CPP Investments
- RA Capital Management
- T. Rowe Price
Highlighted investors led at least one equity round; the number is equity rounds taken part in.
Related companies shared investors
Parabilis MedicinesHealth · $975M in 2025–2026Shared: ARCH Venture Partners, RA Capital Management +1WaymoRobotics · $16B in 2025–2026Shared: Mubadala, Andreessen Horowitz +1CrusoeAI Infra · $5.3B in 2025–2026Shared: Mubadala, T. Rowe PriceKardiganHealth · $554M in 2025–2026Shared: ARCH Venture Partners, T. Rowe PriceDatabricksEnterprise · $10B in 2025–2026Shared: Andreessen Horowitz, Blackstone +1Shield AIDefense · $4.2B in 2025–2026Shared: Andreessen Horowitz, Blackstone
Also in the Austin hub see on the globe
Figures in USD at the time of each round. See the methodology for how rounds are sourced and verified. Ollin Biosciences and its logo are trademarks of their owners, used here for identification only.
